# A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

> **NCT06867497** · PHASE1 · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** BR2021
- **DRUG:** BR2021-1

## Key facts

- **NCT ID:** NCT06867497
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2025-10-28
- **Final completion:** 2025-10-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06867497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06867497, "A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06867497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*